Institut National De La Sante Et De La Recherche Medicale

Université Paris—sud

UniversitÉ De Droit Et De La SantÉ De Lille 2

Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Centre Hospitalier Régional Universitaire De Lille

Université Lille 2 - Droit Et Santé

Ctre Hospitalier Universitaire De Lille

Centre Hospitalier Regionale Universitaire De Lille

Université Paris-Saclay

Université De Lille

Inserm

Sophie Susen

Antoine Rauch

Olivier Christophe

Petrus Lenting

Cécile Denis

Paulette Legendre

Andre Vincentelli

Eric Van Belle

Flavien Vincent

The invention relates to an isolated monoclonal antibody that specifically binds to the D4 domain of VWF, competes for binding to VWF D4 domain with ADAMTS13 and partially inhibits ADAMTS 13-mediated degradation of VWF. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 3 for H-CDR1, SEQ ID NO: 4 for H-CDR2 and SEQ ID NO: 5 for H-CDR3 and a light chain wherein the variable domain comprises at least one CDR having a sequence selected from the group consisting of SEQ ID NO: 7 for L-CDR1, SEQ ID NO: 8 for L-CDR2 and SEQ ID NO: 9 for L-CDR3. Antibodies of the invention are presented to be useful in for the prevention or the treatment of bleeding episodes, such as bleeding episodes occurring in patients with aortic stenosis or patients with ventricular assist devices (VAD).

Antibodies for the prevention or the treatment of bleeding episodes

The present invention relates to a von Willebrand factor composition for the prevention and/or the treatment of haemorrhage and/or bleeding in patients with mechanical circulatory support.

Use of von Willebrand factor

Growing community of inventors

Lille, France

Sophie Susen